Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 686-694

  Hall, Deanne ^a   Buchanan, Julianne ^b   Helms, Bethany ^b   Eberts, Matthew ^b   Mark, Scott ^b   Manolis, Chronis ^b   Peele, Pamela ^b   Docimo, Anne ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Ambulatory; Anticoagulation; Cost savings; Health care spending; Managed care; Pharmacoeconomics; Pharmacy practice

Indexed keywords

WARFARIN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DEEP VEIN THROMBOSIS; DRUG COST; DRUG INDICATION; EMBOLISM; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PORTAL VEIN THROMBOSIS; PROSTHETIC VALVE THROMBOSIS; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

AGED; AMBULATORY CARE; ANTICOAGULANTS; COHORT STUDIES; COST SAVINGS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WARFARIN;

EID: 79959698374     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.686     Document Type: Article

References (21)

1. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-100. (Pubitemid 26372785)
2. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158:1641-7.
3. Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 2010;30:330-8.
4. Chamberlain MA, Sageser NA, Rutz D. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Prac 2001;14:16-21. (Pubitemid 33605759)
5. Foss MT, Schoch PH, Sintek CD. Efficient operation of a high-volume anticoagulation clinic. Am J Health Syst Pharm 1999;56:443-9.
6. Malik AK, Taylor AJ. Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. South Med J 2000;93:58-61. (Pubitemid 30058990)
7. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
8. Poon IO, Lal L, Brown NE, Braun UK. The impact of pharmacist-managed oral anticoagulation therapy in older veterans. J Clinl Pharm Ther 2007;32:21-9. (Pubitemid 46213938)
9. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacy-managed anticoagulation service. Pharmacotherapy 1995;15:732-9.
10. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunenann HJ, for the American College of Chest Physicians. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008; 133(suppl 6):S71-109.
11. The Joint Commission. 2010 national patient safety goals. Available from http://www.jointcommission.org/NR/rdonlyres/ 868C9E07-037F-433D-8858- 0D5FAA4322F2/0/July2010NPSGs-Scoring-HAP2.pdf. Accessed May 12, 2010.
12. Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31-7. (Pubitemid 30060936)
13. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004;10:159-65.
14. Bussey HI. The financial viability of an anticoagulation clinic: a discussion from the anticoagulation forum meeting, May 2009. J Thromb Thrombolysis 2010;29:227-32.
15. Nutescu EA. Anticoagulation management services: entering a new era. Pharmacotherapy 2010;30:327-9.
16. Snyder CM, Helms BE, Hall DL. Evaluation on INR monitoring frequency and time in therapeutic range. J Pharm Technol 2008;24:255-9.
17. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(suppl 6):S160-98.
18. Charlson ME, Pompci P, Alcs KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
20. Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9. (Pubitemid 23069000)
21. Staresinic AG, Sorkness CA, Goodman BM, Pigarelli DW. Comparison of outcomes using 2 delivery models of anticoagulation care. Arch Int Med 2006;166:97-1002.